Targeted Platforms for Life-Threatening Emergencies
RapiGenes delivers autoinjector-based combination product solutions engineered around two critical emergency medicine domains: traumatic injury and CBRN threats.
Rapid Therapeutic Delivery in Mass Casualty & Combat Trauma
Traumatic injury is the leading cause of preventable death in both civilian and military settings. The “Golden Hour” — the critical window in which intervention dramatically improves survival — demands drug delivery systems that match the urgency of the situation.
RapiGenes’ trauma autoinjector platform is designed to bring the ICU to the point of injury. Prefilled, ready-to-use autoinjectors eliminate the preparation steps that delay care in emergency department, prehospital, and combat casualty care (CCC) settings.
- ✓Opioid Analgesics: Prefilled morphine sulfate and fentanyl autoinjectors for battlefield and mass casualty pain management, designed to NATO STANAG and TCCC guidelines
- ✓Naloxone Reversal: High-dose naloxone autoinjector for opioid overdose reversal and opioid-induced respiratory depression in trauma resuscitation
- ✓Tranexamic Acid (TXA): Autoinjector-delivered TXA for prehospital hemorrhage control — the standard of care in TCCC now available without IV access
- ✓Epinephrine: Anaphylaxis and cardiac arrest applications with human-factors-optimized design for lay user and first responder settings
- ✓Ketamine: Sub-dissociative dose autoinjector for prehospital analgesia and procedural sedation in austere environments
Medical Countermeasures for Chemical, Biological, Radiological & Nuclear Threats
CBRN threats — whether from nation-state actors, terrorist organizations, or industrial accidents — demand medical countermeasures that can be deployed rapidly, by responders wearing full PPE, often in chaotic mass-casualty scenarios.
RapiGenes’ CBRN autoinjector platform is developed in alignment with BARDA, DoD Chemical and Biological Medical Systems (CBMS), and the Strategic National Stockpile (SNS) acquisition criteria — purpose-built to meet government procurement requirements while delivering clinical-grade efficacy.
- ✓Nerve Agent Antidotes (Chemical): Atropine and pralidoxime chloride (2-PAM Cl) autoinjectors for organophosphate and nerve agent (sarin, VX, novichok) exposure
- ✓Anticonvulsants (Chemical): Diazepam and midazolam autoinjectors for nerve agent-induced seizure management per DoD TCCC and CHEMPACK protocols
- ✓Radiation Mitigators (Radiological/Nuclear): Filgrastim and Sargramostim autoinjectors for Acute Radiation Syndrome (ARS) — aligned with FDA animal rule approval pathway
- ✓Biological Threat Countermeasures: Platform capability for post-exposure anthrax antitoxin, botulinum antitoxin, and emerging biological threat countermeasure deployment